This mechanism is likely relevant in the presence of the AMD-associated 402H variant of factor H, which has a more restricted specificity for sulfated GAGs compared to 402Y, and likely has decreased ability to control complement activation at ECM sites, such as the BrM (Clark and Bishop, 2018). The gene discussed is CFH; the disease is age-related macular degeneration.